Suppr超能文献

2004-2019 年,马尼托巴省高级别浆液性卵巢癌人群的转诊、遗传咨询和检测。

Referral, Genetic Counselling, and Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004-2019.

机构信息

Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada.

CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB R3E OV9, Canada.

出版信息

Curr Oncol. 2022 Nov 30;29(12):9365-9376. doi: 10.3390/curroncol29120735.

Abstract

(1) Background: The primary objective of this study was to examine the rate of genetic referral, BRCA testing, and BRCA positivity amongst all patients with high-grade serous ovarian cancers (HGSOC) from 2004-2019. The secondary objective was to analyze secondary factors that may affect the rates of referral and testing. (2) Methods: This population-based cohort study included all women diagnosed with HGSOC using the Manitoba Cancer Registry, CervixCheck registry, database at Manitoba Health, the Hospital Discharge abstract, the Population Registry, and Winnipeg Regional Health Authority genetics data. Data were examined for three different time cohorts (2004-2013, 2014-2016; 2017-2019) correlating to practice pattern changes. (3) Results: A total of 944 patients were diagnosed with HGSOC. The rate of genetic referrals changed over the three timeframes (20.0% → 56.7% → 36.6%) and rate of genetic testing increased over the entire timeframe. Factors found to increase rates of referral and testing included age, histology, history of oral contraceptive use, and family history of ovarian cancer. Prior health care utilization indicators did not affect genetic referral or testing. (4) Conclusion: The rate of genetic referral (2004-2016) and testing (2004-2019) for patients with a diagnosis of HGSOC increased over time. A minority of patients received a consultation for genetics counselling, and even fewer received testing for a . Without a genetic result, it is difficult for clinicians to inform treatment decisions. Additional efforts are needed to increase genetics consultation and testing for Manitoban patients with HGSOC. Effects of routine tumour testing on rates of genetic referral will have to be examined in future studies.

摘要

(1) 背景:本研究的主要目的是调查 2004 年至 2019 年期间所有高级别浆液性卵巢癌(HGSOC)患者的基因转诊、BRCA 检测和 BRCA 阳性率。次要目的是分析可能影响转诊和检测率的次要因素。(2) 方法:本基于人群的队列研究纳入了使用曼尼托巴癌症登记处、CervixCheck 登记处、曼尼托巴省卫生数据库、医院出院摘要、人口登记处和温尼伯地区卫生当局遗传数据诊断为 HGSOC 的所有女性。研究了三个不同的时间队列(2004-2013 年、2014-2016 年;2017-2019 年)的数据,以关联实践模式的变化。(3) 结果:共有 944 名患者被诊断为 HGSOC。基因转诊率在三个时间框架内发生变化(20.0%→56.7%→36.6%),基因检测率在整个时间框架内增加。发现增加转诊和检测率的因素包括年龄、组织学、口服避孕药使用史和卵巢癌家族史。先前的医疗保健利用指标不影响基因转诊或检测。(4) 结论:HGSOC 患者的基因转诊率(2004-2016 年)和检测率(2004-2019 年)随时间推移而增加。少数患者接受了遗传咨询,更少的患者接受了 BRCA 检测。没有遗传结果,临床医生很难告知治疗决策。需要进一步努力,增加曼尼托巴 HGSOC 患者的遗传咨询和检测。未来的研究需要检验常规肿瘤检测对基因转诊率的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43a8/9777417/161844d1702d/curroncol-29-00735-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验